Liu X, Yao DL, Webster H: Insulin-like growth factor I treatment reduces clinical deficits and lesion severity in acute demyelinating experimental autoimmune encephalomyelitis
The global market for glucagon-like peptide 1 (GLP-1) agonists segmented by product (condition/brand) [type 2 diabetes [Byetta (exenatide), Victoza (liraglutide), Bydureon BCise (exenatide), Trulicity (dulaglutide), Soliqua (lixisenatide/insulin glargine) FDC, Xultophy / iDegLira (liraglutide / insulin degludec) FDC, Ozempic (semaglutide), Rybelsus (semaglutide), Mounjaro (tirzepatide)], obesity & weight loss management [Saxenda (liraglutide), Wegovy (semaglutide), Zepbound (tirzepatide)]], route of administration (subcutaneous, oral), pipeline analysis, and geography
The Fasting-Autoimmunity Connection The first and arguably most important thing to understand when it comes to the fasting-autoimmunity connection is that autoimmunity is a sign that something has gone wrong with the way the body is working
Newer and more potent GLP1RAs are now available for clinical use, and several randomised clinical trials involving different treatment durations and different GLP1RA doses have been initiated, which may pave the road for further investigation of the potential role of GLP1RAs in the medical treatment of AUD and other addictive disorders
Consider training materials, guideline documents, and peer-reviewed literature when evaluating treatment options
Its also low-sugar, gluten-free, gelatin-free, and third-party tested
